United Therapeutics names Victor Dzau to board of directors

United Therapeutics Corporation announced on July 23, 2026 that its Board of Directors had appointed Victor Dzau, M.D. to the board, effective July 22, 2026. The Board acted on the recommendation of its Nominating and Governance Committee, increasing the board's size to 13 members.¹

Dzau brings an extensive background in academic medicine. He recently completed a 12-year tenure as President of the National Academy of Medicine and had earlier held leadership roles at Duke University, including running its health system, along with academic medicine posts at Harvard and Stanford.¹ After his NAM term ended in June 2026, he returned to Duke in July 2026 in several roles tied to health affairs and medical education, and he also holds a co-chair position on a G20 panel focused on pandemic preparedness financing.¹

The filing states the Board determined that Dr. Dzau will not serve on a Board committee initially.¹ It also notes no arrangement or agreement existed that led to his selection as a director.¹ The company further disclosed no related-party transactions exceeding $120,000 involving Dzau over the past fiscal year through the present.¹

As compensation for joining, Dzau received 380 restricted stock units and 1,190 stock options as an initial grant, plus 350 restricted stock units and 1,110 stock options as a pro-rata grant for the remainder of the 2026-2027 board service year.¹ These awards were granted July 22, 2026 under the company's standard non-employee director compensation program, as detailed in its April 29, 2026 proxy statement.¹ Dzau also signed the company's standard director and officer indemnification agreement, effective the same day.¹